Amylyx Pharmaceuticals annual r&d spending
2021
2022
2023
2024
2025
Amylyx Pharmaceuticals R&D Spending Growth & History (AMLX)
Amylyx Pharmaceuticals's r&d spending was $90.4M for fiscal 2025.
View full Amylyx Pharmaceuticals company overviewAmylyx Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $90.4M | −$13.7M | −13.14% |
| 2024 | 2024-12-31 | $104.1M | $101.4M | +3754.96% |
| 2023 | 2023-12-31 | $2.7M | −$20.2M | −88.21% |
| 2022 | 2022-12-31 | $22.9M | −$21.1M | −48.00% |
| 2021 | 2021-12-31 | $44.0M | — | — |
Amylyx Pharmaceuticals quarterly r&d spending
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $23.8M | −$3.4M | −12.67% |
| Q1 2026 | 2026-03-31 | $27.6M | $5.5M | +24.82% |
| Q4 2025 | 2025-12-31 | $21.2M | −$1.7M | −7.33% |
| Q3 2025 | 2025-09-30 | $19.9M | −$1.4M | −6.51% |
| Q2 2025 | 2025-06-30 | $27.2M | $3.9M | +16.58% |
| Q1 2025 | 2025-03-31 | $22.1M | −$14.5M | −39.58% |
| Q4 2024 | 2024-12-31 | $22.9M | — | — |
| Q3 2024 | 2024-09-30 | $21.2M | −$8.8M | −29.30% |
| Q2 2024 | 2024-06-30 | $23.3M | −$5.7M | −19.62% |
| Q1 2024 | 2024-03-31 | $36.6M | $18.5M | +102.25% |
| Q3 2023 | 2023-09-30 | $30.0M | $5.1M | +20.56% |
| Q2 2023 | 2023-06-30 | $29.0M | $4.8M | +19.72% |
| Q1 2023 | 2023-03-31 | $18.1M | −$3.4M | −15.67% |
| Q3 2022 | 2022-09-30 | $24.9M | $12.1M | +93.84% |
| Q2 2022 | 2022-06-30 | $24.3M | $13.3M | +121.97% |
| Q1 2022 | 2022-03-31 | $21.5M | $14.6M | +212.70% |
| Q4 2021 | 2021-12-31 | $13.4M | — | — |
| Q3 2021 | 2021-09-30 | $12.9M | — | — |
| Q2 2021 | 2021-06-30 | $10.9M | — | — |
| Q1 2021 | 2021-03-31 | $6.9M | — | — |
Amylyx Pharmaceuticals r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, Amylyx Pharmaceuticals's r&d spending increased from $44.0M to $90.4M, a change of $46.4M. The latest reported quarter, Q2 2026, shows $23.8M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amylyx Pharmaceuticals source filings ↗